Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
61.63
Nov 04 • 3:59 PM ET Dollar change+0.88 Percentage change(1.45%)
Aftermarket Close
61.63
Aftermarket • 4:33 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
9.43B
Enterprise Value
9.64B
Income
441.49M
Sales
799.54M
Book/sh
3.95
Cash/sh
3.61
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
399
IPO
Dec 14, 1995
P/E
22.45
Forward P/E
21.44
PEG
2.12
P/S
11.80
P/B
15.62
P/C
17.08
P/FCF
542.48
EV/EBITDA
70.08
EV/Sales
12.05
Quick Ratio
3.72
Current Ratio
4.27
Debt/Eq
1.25
LT Debt/Eq
1.25
Option/Short
Yes / Yes
EPS (ttm)
2.75
EPS next Y
2.87
EPS next Q
0.37
EPS this Y
-63.91%
EPS next Y
187.56%
EPS next 5Y
10.12%
EPS past 3/5Y
- -
Sales past 3/5Y
504.86% 426.73%
EPS Y/Y TTM
634.54%
Sales Y/Y TTM
76.08%
EPS Q/Q
-71.45%
Sales Q/Q
70.27%
Insider Own
7.47%
Insider Trans
-0.04%
Inst Own
73.24%
Inst Trans
3.50%
ROA
37.70%
ROE
100.28%
ROIC
32.54%
Gross Margin
82.37%
Oper. Margin
17.05%
Profit Margin
55.22%
SMA20
9.93%
SMA50
10.72%
SMA200
39.25%
Trades
Shs Outstand
153.08M
Shs Float
141.64M
52W High
63.60 -3.10%
52W Low
26.76 130.31%
Volatility
4.73% 4.31%
ATR (14)
2.44
RSI (14)
68.08
Beta
1.81
Rel Volume
1.04
Avg Volume
1.81M
Volume
1,884,460
Perf Week
7.37%
Perf Month
18.09%
Perf Quarter
24.38%
Perf Half Y
46.84%
Perf YTD
106.74%
Perf Year
82.28%
Perf 3Y
457.23%
Perf 5Y
76.84%
Perf 10Y
1073.90%
Prev Close
60.75
Price
61.63
Change %
1.45%
Consensus
Strong Buy
Avg. Price Target
$69.71
Implied Upside
+13.1%
Analysts11incl. previous ratings
Rating Distribution9 Buy · 1 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 06, 2025Resumed
HH.C. Wainwright
Buy$60-2.6%
Jul 10, 2025Resumed
GS logoGGoldman
Neutral$37-40.0%
Oct 29, 2024Initiated
TD logoTTD Cowen
Buy$50-18.9%
Aug 02, 2023Upgrade
GS logoGGoldman
Sell → Neutral$16 → $12-80.5%
Jun 26, 2023Resumed
JEF logoJJefferies
Buy$55 → $40-35.1%
May 20, 2022Initiated
BAC logoBBofA Securities
Underperform$5-91.9%
Feb 23, 2022Reiterated
RILY logoRB. Riley Securities
Buy$49 → $35-43.2%
Nov 15, 2021Downgrade
GS logoGGoldman
Neutral → Sell$33 → $26-57.8%
Apr 20, 2021Initiated
GS logoGGoldman
Neutral$50-18.9%
Apr 19, 2021Reiterated
HH.C. Wainwright
Buy$79 → $89+44.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Charney Laurence NDirectorSep 10 '26Sale54.965,000274,800168,640Sep 14 05:00 PM
Charney Laurence NDirectorSep 10 '26Proposed Sale54.965,000274,794Sep 10 04:46 PM
Echelard YannDirectorNov 24 '25Sale32.575,000162,850223,816Nov 25 05:31 PM
Echelard YannDirectorNov 24 '25Proposed Sale32.575,000162,850Nov 24 04:04 PM
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
J.D.Mr. Michael S. Weiss Esq.
CFOMr. Sean A. Power CPA
Senior Vice President of Corporate CommunicationsMs. Jenna Bosco
Chief Commercialization OfficerMr. Adam Waldman